Evidence map›Paper›PMID 42628532›Full record

ArticleMolecular cell2026

Nicotinamide nucleotide transhydrogenase directly couples redox homeostasis to proline biosynthesis in human glioma.

Lisa A Vettore, Adam Boufersaoui, Yingying Lyu, Anaïs Oudin, Keene L Abbott, Sonu Subudhi, Yetiş Gültekin, Katherine L Eales, Ishana Rajgopal, Cristina Escribano-Gonzalez and 7 more

Abstract read
In one paragraph

Article in Molecular cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lisa A VettoreDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Adam BoufersaouiDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Department of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Yingying LyuDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Anaïs OudinNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg; Animal Facility, Department of Cancer Research, Luxembourg Institute of Health, 4354 Esch-sur-Alzette, Luxembourg.
Keene L AbbottKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Sonu SubudhiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Harvard Medical School, Boston, MA, USA.
Yetiş GültekinKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Katherine L EalesDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Ishana RajgopalDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Cristina Escribano-GonzalezDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Rahatil A ChowdhuryDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Himani RanaDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
Victoria WykesDepartment of Cancer and Genomic Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK; Department of Neurosurgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2GW, UK.
Rakesh K JainEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Anna GolebiewskaNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, 1210 Luxembourg, Luxembourg.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Daniel A TennantDepartment of Metabolism and Systems Science, College of Medicine and Health, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK. Electronic address: d.tennant@bham.ac.uk.

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Understanding the role of metabolism in cancerR35CA242379 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI VANDER HEIDEN, MATTHEW G. · 2019 to 2025
$5.8M
Dissecting Pediatric Brain Tumor Microenvironment to Improve TreatmentR35CA197743 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K. · 2015 to 2020
$5.7M
Targeting physical stress-driven mechanisms to overcome glioblastoma treatment resistanceU01CA261842 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., MUNN, LANCE L. · 2021 to 2025
$3.1M
Reprogramming PDAC tumor microenvironment to improve immunotherapyU01CA224348 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BOUCHER, YVES, JAIN, RAKESH K. · 2017 to 2021
$2.9M
Improving treatment of HER2+ breast cancer brain metastasis by targeting lipid metabolismR01CA259253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JAIN, RAKESH K., VANDER HEIDEN, MATTHEW G. · 2021 to 2025
$2.3M
Reengineering obesity-induced abnormal microenvironment to improve PDAC treatmentR01CA208205 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FUKUMURA, DAI, JAIN, RAKESH K. · 2017 to 2020
$2.2M
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA208205NCI NIH HHS R01 CA259253NCI NIH HHS R35 CA197743NCI NIH HHS R35 CA242379NCI NIH HHS U01 CA224348NCI NIH HHS U01 CA261842
6 · The paper itself

Abstract

Cancer cell proliferation requires a precise balance between biomass production and nutrient catabolism. The pyridine nucleotide cofactors nicotinamide adenine dinucleotide NAD(H) and NAD phosphate NADP(H) are central to this process, but their compartment-specific regulation is incompletely understood. Using in vivo isotope-labeled metabolite tracing in an orthotopic xenograft model, we find that human gliomas extensively synthesize proline, an amino acid previously associated with hypoxia tolerance. In glioma cells, we identify a hypoxia-enhanced proliferative sensitivity to environmental proline dependent on NADH to NADPH transhydrogenation from a spatially compartmentalized mitochondrial pool by the enzyme nicotinamide nucleotide transhydrogenase (NNT). We demonstrate NNT-dependent generation of mitochondrial NADPH is important for proline accumulation, maintenance of antioxidant systems, and reductive metabolism in hypoxic glioma cells in vitro and tumor progression in vivo. Collectively, these results highlight proline accumulation as a marker of mitochondrial NAD(P)(H) homeostasis and NNT as a specific metabolic dependency in human glioma.

Indexed as

Brain NeoplasmsGliomaNADP Transhydrogenase, AB-SpecificNADP TranshydrogenasesProlineAnimalsCell Line, TumorCell ProliferationHomeostasisHumansMetabolic ReprogrammingMiceMice, NudeMitochondriaMitochondrial ProteinsNADMitochondrial ProteinsNADNADPNADP Transhydrogenase, AB-SpecificNADP TranshydrogenasesNNT protein, humanProlinegliomahypoxiaNNTprolineredox

Identifiers

PMID42628532
PMCPMC13650111

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.